# Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)

> **NCT02296411** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 98 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CHF 5259 12.5 µg + Qvar
- **DRUG:** CHF 5259 placebo + Qvar

## Key facts

- **NCT ID:** NCT02296411
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-21
- **Primary completion:** 2015-08-13
- **Final completion:** 2015-08-13
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296411, "Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02296411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*